4 news items
Mereo BioPharma Announces Pricing of $50 Million Underwritten Registered Direct Offering of American Depository Shares, Priced At-the-Market
MREO
14 Jun 24
results to differ materially from the Company's historical experience and its present expectations or projections. Such risks and uncertainties include
Ultragenyx and Mereo BioPharma Announce New Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Sustained Reductions in Fracture Rates Following Treatment with Setrusumab (UX143) in Patients with Osteogenesis Imperfecta (OI)
MREO
RARE
11 Jun 24
information about the company, including information that may be deemed material to investors, and to comply with its disclosure obligations under Regulation
Mereo BioPharma to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
MREO
3 Apr 24
control and assumptions that could cause actual results to differ materially from the Company's historical experience and its present expectations
Mereo BioPharma Reports Full Year 2023 Financial Results and Provides Corporate Update
MREO
27 Mar 24
and assumptions that could cause actual results to differ materially from the Company's historical experience and its present expectations or projections
- Prev
- 1
- Next